|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Medicine and Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106
The oncogene bcl-2 encodes a 26-kD protein
localized to intracellular membranes, including the ER,
mitochondria, and perinuclear membrane, but its
mechanism of action is unknown. We have been investigating the hypothesis that Bcl-2 regulates the movement of calcium ions (Ca2+) through the ER membrane. Earlier findings in this laboratory indicated that
Bcl-2 reduces Ca2+ efflux from the ER lumen in
WEHI7.2 lymphoma cells treated with the Ca2+-ATPase inhibitor thapsigargin (TG) but does not prevent
capacitative entry of extracellular calcium. In this report, we show that sustained elevation of cytosolic Ca2+
due to capacitative entry is not required for induction
of apoptosis by TG, suggesting that ER calcium pool
depletion may trigger apoptosis. Bcl-2 overexpression
maintains Ca2+ uptake in the ER of TG-treated cells
and prevents a TG-imposed delay in intralumenal processing of the endogenous glycoprotein cathepsin D. Also, Bcl-2 overexpression preserves the ER Ca2+ pool
in untreated cells when extracellular Ca2+ is low. However, low extracellular Ca2+ reduces the antiapoptotic
action of Bcl-2, suggesting that cytosolic Ca2+ elevation
due to capacitative entry may be required for optimal ER pool filling and apoptosis inhibition by Bcl-2. In
summary, the findings suggest that Bcl-2 maintains
Ca2+ homeostasis within the ER, thereby inhibiting
apoptosis induction by TG.
This article has been cited by other articles:
|
|